Five-membered heterocyclic compounds

Details Five-membered heterocyclic compounds Five-membered heterocyclic compounds

2008-05-06

2008-05-06

Anderson, Rebecca (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S215000, C548S225000, C548S233000, C548S243000, C548S245000, C548S247000, C514S374000, C514S376000, C514S377000, C514S378000, C514S380000

Reexamination Certificate

active

10527426

ABSTRACT:
The present invention provides a compound represented by the formula:wherein R1is an optionally substituted 5-membered heterocyclic group; X, Y and V are the same or different and each is a bond, an oxygen atom, a sulfur atom and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is —(CH2)n-Z1- or -Z1-(CH2)n— (n is an integer of 0 to 8, Z1is a bond, an oxygen atom, a sulfur atom and the like); ring B is a nitrogen-containing heterocycle optionally further having 1 to 3 substituents; W is a bond or a divalent hydrocarbon group having 1 to 20 carbon atoms; R2is a hydrogen atom, a cyano group, —PO(OR9)(OR10) (R9and R10are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, and R9and R10are optionally bonded to form an optionally substituted ring) and the like, or a salt thereof, which has a superior adipose tissue weight decreasing action, a hypoglycemic action and a hypolipidemic action, and which is useful as an agent for the prophylaxis or treatment of obesity, diabetes mellitus, hyperlipidemia, impaired glucose tolerance, hypertension and the like.

REFERENCES:
patent: 4171365 (1979-10-01), Diana et al.
patent: 4996216 (1991-02-01), Leyendecker et al.
patent: 6214842 (2001-04-01), Malamas et al.
patent: 2 110 211 (1983-06-01), None
patent: 63159373 (1988-07-01), None
patent: WO J96/13264 (1996-05-01), None
patent: WO 00/64876 (2000-11-01), None
patent: WO 01/00603 (2001-01-01), None
patent: WO 01/16111 (2001-03-01), None
patent: WO 01/17994 (2001-03-01), None
patent: WO 01/38325 (2001-05-01), None
patent: WO 01-16111 (2001-08-01), None
patent: WO 02/053547 (2002-07-01), None
patent: WO 02/076959 (2002-10-01), None
patent: WO 03/000685 (2003-01-01), None
patent: WO 03/015774 (2003-02-01), None
http://dictionary.reference.com/browse/prophylaxis, p. 1 of 4.
Rieusset et al., A New Selective Peroxisome Proliferator-Activated Receptor gamma Antagonist with Antiobesity and Antidiabetic Activity, abstract (pp. 1 and 2 of 6).
He et al., Adipose-specific peroxisome proliferator-activated receptor (gamma) knockout causes insulin resistance in fat and liver but not in muscle, PNAS, vol. 100, No. 26, pp. 15712-15717.
Ryan et al., PPAR gamma Agonist Rosiglitazone Improves Vascular Function and Lowers Blood Pressure in Hypertensive Transgenic Mice, abstract (pp. 1 and 2 of 4).
Hung et al., Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance, abstract (pp. 1 and 2 of 3).
http://diabetes.webmd.com/guide/preventing-type-2-diabetes, pp. 1-2 of 2.
http://diabetes.webmd.com/tc/Prediabetes-Topic-Overview, p. 2 and 3 of 3.
http://diabetes.webmd.com/guide/insulin-resistance-syndrome, p. 1 of 1.
http://www.webmd.com/diet/tc/Obesity-Overview, p. 1-3-2 of 3.
http://www.webmd.com/hypertension-high-blood-pressure/guide/preventing-high-blood-pressure?page=2, pp. 1-2 of 2.
http://jcem.endojournals.org/cgi/content/full/90/3/0, pp. 1-4 of 4.
Farmer et al., “Aza-retinoids as novel retinoid x receptor specific agonists”, bioorganic&medicinal chemistry letters, 16, 2006, 2352-2356.
Rieusset et al, “A new selective peroxisome proliferator-activated receptor antagonist with antiobesity and antidiabetic activity”, molecular endocrinology 16 (11), 2628-2644, abstract (2 pages).
http://www.healthatoz.com/healthatoz/Atoz/common/standard/transform.jsp?requestURI=/healthatoz/Atoz/dc/cen/card/hypr/hypertreat.jsp.
http://www.medicinenet. com/diabetes—treatment/ article.htm.
http://www.webmd.com/diet/tc/Obesity-Overview.
Rieusset et al., “A New Selective Peroxisome Proliferator-Activated Receptor g Antagonist with Antiobesity and antidiabetic Activity”, Mol. Endocrinology, 16, 11, 2628-2644.
E. Winkelmann, et al., “Chemotherapeutically Active Nitro Compounds”, Arzneim-Forsch./Drug Res. 28(I), Heft 5, (1978), pp. 739-749.
E. Winkelmann, et al., “Chemotherapeutically Active Nitro Compounds”, Arzneim-Forsch./Drug Res. 28(I), Heft 3, (1978), pp. 351-366.
Yu Momose, et al., “Novel 5-Substituted-1H-tetrazole Derivatives as Potent Glucose and Lipid Lowering Agents”, Chem. Pharm. Bull., (2002), pp. 100-111, vol. 50, No. 1.
John J. Baldwin, et al., “Beta 1-Selective Adrenoceptor Antagonists: Examples of the 2-[4-[3-(Substituted amino)-2-hydroxypropoxy]phenyl]imidazole Class. 2”, Journal of Medicinal Chemistry, (1986), pp. j1065-j1080, vol. 29, No. 6.
Yu Momose, et al., “Novel 5-Substituted 2,4-Thiazolidinedione and 2,4-Oxazolidinedione Derivatives as Insuline Sensitizers with Antidiabetic Activities”, J. Med. chem., (2002), pp. 1518-1534, vol. 45, No. 7.

Affiliated with

Also associated with

Rating

Five-membered heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Five-membered heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Five-membered heterocyclic compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3944339